Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CaliPharms, Inc. (OTC: KGET) appears to be a publicly traded micro-cap company quoted on the OTC market. Based on available public disclosures and historical OTC market references, the company has been associated with activities tied to the cannabis, hemp, and wellness sectors, including product distribution and brand development. However, the scope of its active operations, current revenue-generating activities, and corporate structure are difficult to independently verify from recent comprehensive filings.
Publicly available information regarding the company’s operational history, audited financial performance, and current strategic direction is limited and, in some cases, inconsistent across market databases and legacy corporate materials. Data inconclusive based on available public sources regarding the company’s current commercial scale, active product portfolio, and sustained operating business lines.
Business Operations
Historical OTC disclosures and market references indicate the company has explored business activities related to hemp-derived consumer products, cannabis-adjacent branding, and distribution arrangements. Some historical materials reference interests in extraction, wellness products, and licensing-oriented opportunities. However, recent independently verifiable operational details, including active subsidiaries, material customer relationships, or recurring revenue sources, are not sufficiently documented in publicly accessible filings.
There is limited verifiable information concerning international operations, proprietary technologies, strategic assets, or material joint ventures. No consistently documented evidence was identified confirming large-scale operating infrastructure, manufacturing ownership, or long-term commercial partnerships. Data inconclusive based on available public sources regarding the company’s present operational footprint and business segment structure.
Strategic Position & Investments
Historically, the company has appeared to position itself within the broader cannabis and hemp consumer-products ecosystem, a sector characterized by evolving regulatory frameworks and fragmented market participation. Public references suggest the company pursued opportunities tied to emerging wellness and cannabinoid-related markets, though recent validated disclosures detailing execution progress, capital deployment, or measurable market share remain limited.
No major acquisitions, institutional investments, or significant portfolio holdings could be consistently verified through widely available public filings and independent financial reporting sources. Similarly, there is insufficient reliable information confirming meaningful exposure to advanced cannabis technologies, pharmaceutical development, or large-scale vertically integrated operations. Data inconclusive based on available public sources.
Geographic Footprint
CaliPharms, Inc. appears to be headquartered in the United States and trades through the U.S. OTC market system. Public references primarily associate the company with domestic business activity rather than a broad multinational operating network.
There is no consistently verified evidence of significant operational presence across Europe, Asia-Pacific, Latin America, or other major international regions. Available public information does not clearly establish substantial foreign subsidiaries, international manufacturing facilities, or cross-border investment operations.
Leadership & Governance
Publicly available governance and executive information for CaliPharms, Inc. is limited and not consistently updated across regulatory databases and market information services. Due to the absence of recent comprehensive reporting and verified disclosures, certain leadership positions and governance structures cannot be conclusively confirmed.
Known or historically referenced executives associated with the company in public market materials include:
- David Lovatt – Former executive and corporate officer references appear in historical OTC-related materials
- Data inconclusive based on available public sources regarding current executive leadership, board composition, and active management structure
The company’s broader governance philosophy, long-term strategic vision, and management priorities are not clearly documented in recent independently verifiable public disclosures.